NCT05400070 2024-10-18Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLCTang-Du HospitalPhase 2 Active not recruiting45 enrolled